Roger Adami

Roger Adami, Ph.D. is Chief Technology Officer at Land Therapeutics Inc., where he leads the development of targeted gene editing therapeutics aimed at treating genetic diseases with high precision and efficacy. In this role, Dr. Adami oversees scientific strategy, platform innovation, and cross-functional R&D teams focused on advancing next-generation gene editing therapeutics.

Prior to joining Land Therapeutics, Dr. Adami served as Vice President of Pharmaceutical Sciences and Business Development at Nitto BioPharma Inc. in San Diego, California. He led the Drug Delivery System (DDS) platform research, pioneering novel lipid nanoparticle technologies for the delivery of RNA and DNA therapeutics to specific organs and developed LNP clinical candidates. He directed multidisciplinary teams across chemistry, formulation, targeting, analytical, process development, manufacturing and CMC, while also spearheading strategic partnerships and business development initiatives.

Prior to Nitto, Dr. Adami was Director of Formulations at Marina Biotech, a Seattle-based company focused on siRNA therapeutics. He also founded and served as CEO of Permesys, a personalized medicine startup. He began his pharmaceutical career at Pfizer Inc. in Groton, Connecticut, specializing in parenteral formulation and product development.

Dr. Adami holds a Ph.D. in pharmaceutics from the University of Michigan, Ann Arbor, where his research focused on peptide-based DNA gene therapy vectors. He also earned a master’s degree in chemical engineering and a bachelor’s degree in Biochemistry from the University of Illinois, Chicago.